> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Axogen Raised $225 Million In Stock Weeks Before Spending About $200 Million On BioCircuit
- URL: https://www.bullished.co/axogen-raised-225-million-in-stock-weeks-before-spending-about-200-million-on-biocircuit-d0cc8543/
- Published: 2026-10-28T20:26:36.000Z
- Updated: 2026-10-28T20:26:36.000Z
- Description: Axogen's $348 million cash pile at quarter-end was largely a bridge to a cash acquisition that closed October 1.
- Author: Matteo Parrino
- Tags: Deals, AXGN, Industry: Healthcare

[Axogen](https://www.bullished.co/tag/axgn/), which makes products surgeons use to repair damaged peripheral nerves, ended September with [$348 million in cash and investments](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000108/axgn-20260930.htm?ref=bullished.co) — and about $200 million of it left the next day to buy BioCircuit, the maker of NerveTape, according to its 10-Q filed Wednesday. A September stock sale raised the money the deal consumed.

## A stock sale that funded the deal

Cash and investments stood at $348,068 thousand on September 30, against $111,412 thousand in the [prior quarterly filing](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000094/axgn-20260630.htm?ref=bullished.co). The jump came from the sale of 5,646,500 shares at $42.50, which brought in $225,029 thousand net. The first tranche closed September 11 and the over-allotment tranche September 16.

On October 1 Axogen completed the BioCircuit purchase. The base price was $200,000 thousand in cash, subject to adjustments, with $1,000 thousand withheld at closing for post-closing adjustments. The company says it factored the outlay into its liquidity assessment and still expects its cash and product sales to fund operations for at least twelve months.

Transaction costs were $1,883 thousand in the third quarter, and Axogen estimates about $5,000 thousand more in the fourth quarter. The initial purchase accounting is not finished.

## Integration risk and a bigger share count

The 10-Q adds a risk factor warning that Axogen may not realize the merger's anticipated benefits, or may realize them more slowly than expected. It also says integrating BioCircuit could be difficult, costly and a drain on management's attention.

The share count is climbing. Weighted diluted shares were 61,525,789 in the third quarter, against 49,088,436 a year earlier. In January, Axogen sold 4,600,000 shares at $31.00 to pay off its Oberland credit facility, which booked a $16,849 thousand loss on extinguishment of debt. The balance sheet now shows no long-term debt.

## The quarter underneath the deal

Third-quarter [revenue](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000106/ex991axgnearningsreleaseda.htm?ref=bullished.co) rose 26.2% to $75.8 million. Net income was $2.3 million, or $0.04 a share, against $0.7 million a year earlier. Gross margin slipped to 74.8% from 76.6%, which the 10-Q attributes to higher product costs.

For the first nine months, Axogen reported a net loss of $18,766 thousand, including the debt-extinguishment loss. The company raised 2026 revenue guidance to at least $290 million, including at least $7 million from BioCircuit, and still expects positive free cash flow for the year.

Axogen also bought an [18.9% preferred-stock stake](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000108/axgn-20260930.htm?ref=bullished.co) in Trace Biosciences, a privately held biotech, for $7,000 thousand. The stake carries at $7,008 thousand.

Axogen will host a prostate-focused investor call on November 9 at 9:00 a.m., after deciding to start prostate market development in 2027.

### Sources

- [10-Q Filing — Axogen (AXGN)](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000108/axgn-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Axogen (AXGN), Q2 FY2026 filed 2026-07-29 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000094/axgn-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, ex991axgnearningsreleaseda.htm) — Axogen, filed 2026-10-28](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000106/ex991axgnearningsreleaseda.htm?ref=bullished.co) — SEC EDGAR
- [Axogen Shares Rise After Higher 3Q Revenue, Earnings](https://www.marketwatch.com/story/axogen-shares-rise-after-higher-3q-revenue-earnings-d4ec3b4c?ref=bullished.co) — MarketWatch
- [Axogen Soars 29% on Q3 Beat, Lifts 2026 Revenue Guidance to at Least $290 Million](https://finance.yahoo.com/markets/stocks/articles/axogen-soars-29-q3-beat-161709229.html?ref=bullished.co) — Yahoo Finance
- [AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates](https://finance.yahoo.com/markets/stocks/articles/axogen-axgn-beats-q3-earnings-113503650.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Axogen Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/10/62653118/axogen-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [AxoGen: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/axogen-q3-earnings-snapshot-183633107.html?ref=bullished.co) — Associated Press

### More on Axogen

- [Axogen CFO Says $34 Million Nerve Tape Forecast Is Net Of Cannibalization](https://www.bullished.co/axogen-cfo-says-34-million-nerve-tape-forecast-is-net-of-cannibalization-541cd6e9/)
- [Axogen Will Start Prostate Nerve Repair Market Development In 2027, Citing Early Results From 220 Patients](https://www.bullished.co/axogen-will-start-prostate-nerve-repair-market-development-in-2027-citing-early-results-2c940db8/)
- [Axogen Lifts 2026 Revenue Outlook To At Least $290 Million After Third-Quarter Sales Climb 26.2%](https://www.bullished.co/axogen-lifts-2026-revenue-outlook-to-at-least-290-million-after-third-quarter-sales-climb-02735438/)

[All Axogen (AXGN) coverage →](https://www.bullished.co/tag/axgn/)